Disease · MONDO_0008231

Peyronie disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Peyronie disease. Diseases, record MONDO_0008231. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008231

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Peyronie disease; Open Targets
Open Targets ID: MONDO_0008231; Open Targets
Other names: Peyronie's disease, Peyronie's fibromatosis, penile fibromatosis, penile induration, penis fibromatosis; Open Targets
Disease Ontology: DOID:8616; Disease Ontology
NCI Thesaurus: C3316; NCI Thesaurus
Orphanet: ORPHA:2870; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	CHEMBL2108709	Enzyme	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
H-100	CHEMBL4802134	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
TESTOSTERONE	CHEMBL386630	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
HYALURONIC ACID	CHEMBL5314376		Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
VERAPAMIL	CHEMBL6966	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets32

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AR	Androgen receptor	1	Androgen Receptor agonist	Phase 1	https://conductscience.org/library/genes/367	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/779	Drugs and targets
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1301	Drugs and targets
COL11A2	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1302	Drugs and targets
COL15A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1306	Drugs and targets
COL18A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/80781	Drugs and targets
COL1A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1277	Drugs and targets

1 to 10 of 32

See all 32 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01221597	Study of AA4500 in the Treatment of Peyronie's Disease	Phase 3	418	2015-04-07	Peyronie's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT01221623	Study of AA4500 in the Treatment of Peyronie's Disease	Phase 3	418	2015-04-07	Peyronie's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT01243411	A Study of AA4500 in Men With Peyronie's Disease	Phase 3	348	2015-04-15	Peyronie's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT01685437	A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease	Phase 3	189	2015-04-07	Peyronie's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT00755222	The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease	Phase 2	147	2011-04-26	Peyronie's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT01430169	Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease	Phase 2	20	2015-05-06	Peyronie's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT00812838	H-22411: BOTOX® for Peyronie's Disease	Phase 2	12	2020-02-17	Peyronie's Disease	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT01578473	Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease	Phase 1	75		Peyronie's Disease	ERGOCALCIFEROL, TESTOSTERONE, VITAMIN E	Its record names the disease	ClinicalTrials.gov
NCT06065436	Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease	Not applicable	60		Peyronie Disease, Erectile Dysfunction	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT05855070	Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease	Not applicable	42		Peyronie's Disease, Hyaluronic Acid, Verapamil	HYALURONIC ACID, VERAPAMIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AA4500 vs Placebo: serious adverse events	27 of 277	7 of 140	417	NCT01221597	Trial comparisons
AA4500 vs Placebo: serious adverse events	12 of 274	4 of 141	415	NCT01221623	Trial comparisons
AA4500 vs Placebo: serious adverse events	4 of 111	1 of 36	147	NCT00755222	Trial comparisons
100 Units of Botulinum Toxin Type A vs Normal Saline: deaths from any cause	0 of 10	0 of 6	16	NCT00812838	Trial comparisons
100 Units of Botulinum Toxin Type A vs Normal Saline: serious adverse events	0 of 10	0 of 6	16	NCT00812838	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28974406	DERIVED	1	PubMed
26199168	DERIVED	2	PubMed
25388099	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008231

GET https://conductscience.org/api/diseases/v1/MONDO_0008231/targets?page=2

API reference For AI assistants